The goal of this clinical study is to determine impact of carbon ion radiotherapy (CIRT) treatment in combination with systemic therapy for oligo-metastatic prostate cancer. The primary objective: to determine disease biochemical progression-free survival in man with oligo-metastatic (M1a/b) prostate cancer undergoing systemic therapy with definitive radiotherapy of the primary tumor. The secondary objective: to determine local control, overall survival and quality of life in men with oligo-metastatic prostate cancer undergoing carbon ion radiotherapy
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
47
carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
Shanghai Proton and Heavy Ion Center
Shanghai, Shanghai Municipality, China
RECRUITINGTime to PSA relapse
Time frame: From the start of systemic therapy, a median of 2 years
progression free survival
Time frame: From the start of systemic therapy, a median of 2 years
Overall survival
Time frame: From the start of systemic therapy, a median of 2 years
Quality of life
Time frame: From the start of carbon ion radiotherapy, a median of 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.